For anyone that takes the time to look under the hood, it's not about earnings at this point of their story. It is nice to see Erivedge continues to have a nice growth rate.... 28% Q4 to Q3, gives them some cash flow and goes to servicing the $30M financing from 2012. Based on the rate of sales growth, I'm thinking late 2016 or definitely 2017, it will be satisfied. Every month if you don't want to wait for their CC just watch for Roche's breakdown ~ a month b4. Q4 was $42M so assuming 5%, $2.1M in sales. Wondering now that it is over $1M for the year if it bumps up which we would find out at the CC. Ceiling is 7.5%. There typically is some knee jerk reaction from folks not taking the time to digest the whole story...not concerned about them like the day/short term trades moving in and out. I am very much a T\A freak and I just stare at this chart as in the 35 years I've been doing this I've just NEVER seen a chart this parabolic\overbought that shows no negative divergences at this point for such a run. But anyone that knows\been involved in these wars knows overbought conditions with this kind of momentum can go for a long time with no or very little pullbacks.... just go with the trend. I just smile at the people that try to tell the market it is wrong (is it ever?) and step in front of this to short. And I've been there and learned the hard way myself a long time ago. Every level I've identified as a target\resistance has had some selling but unless you look at intraday charts many are not aware of that. Friday the first 20 minutes was amazing as selling\shorting was thrown at it big time and when I saw it hold ~2.90 level just knew this was a beast and would bounce hard! lol I think that has been the beauty of this climb that contrary to what daily charts show, there has been a lot of selling and shorting on the way up to relieve the overbought pressure allowing this to climb insanely. The momentum combined with more people understanding the story of what they're doing, specifically 907 could easily support this to hit my revised targets of 10-15 by year's end; 6 or more by ASCO; and 40 or less within 4 years (and that may be conservative). Right now I'd say the 3.35 area may get a bit sticky and then there is the gap ~ 3.85 to close from when CUDC 427 was halted. My thought there is that is it's a gap that will be the type to close and then this thing will accelerate. Again just an old guy's opinion. fwiw Another wildcard which could be huge for them, again imo, is the IPF trial w\ Erivedge that Roche is slated to resume. A huge market and the fact is Erivedge is antifibrotic and there are MANY fibrotic diseases out there.
